- Home
- RLAY
RLAY
Relay Therapeutics Inc.
as 05-09-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $18.40 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $10.72 | Next Earning Date: | 05-05-2025 |
| Revenue: | $7,679,000 | Revenue Growth: | -78.26% |
| Revenue Growth (this year): | -52.71% | Revenue Growth (next year): | 440.45% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | RLAY | President, R&D | Apr 28 '25 | Sell | $3.09 | 31,562 | $95,381.30 | 583,490 | |
| Rahmer Peter | RLAY | See remarks | Apr 28 '25 | Sell | $3.09 | 12,103 | $36,540.88 | 400,820 | |
| Bergstrom Donald A | RLAY | President, R&D | Mar 27 '25 | Sell | $2.84 | 986 | $2,800.24 | 583,490 | |
| Adams Brian | RLAY | Chief Legal Officer | Mar 27 '25 | Sell | $2.84 | 298 | $846.32 | 405,972 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Mar 27 '25 | Sell | $2.84 | 4,864 | $13,813.76 | 374,567 | |
| Rahmer Peter | RLAY | See remarks | Mar 27 '25 | Sell | $2.84 | 247 | $701.48 | 400,820 | |
| Patel Sanjiv | RLAY | President and CEO | Feb 11 '25 | Sell | $3.78 | 215,506 | $818,399.50 | 625,948 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Insider Monkey
2 days ago
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
GlobeNewswire
4 days ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
11 days ago
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Argus Research
15 days ago
Daily – Vickers Top Buyers & Sellers for 04/25/2025
Insider Monkey
20 days ago
Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts
MT Newswires
23 days ago
Wells Fargo Initiates Relay Therapeutics at Equalweight With $4 Price Target
Insider Monkey
23 days ago
Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.